Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F DiPersio

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Blood|December 10, 1999
Ex vivo cultured megakaryocytes express functional glycoprotein IIb-IIIa receptors and are capable of adenovirus-mediated transgene expressionN Faraday, J J Rade, D C Johns, et al.
Bone Marrow Transplantation|January 14, 2009
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATGM G Martin, G L Uy, E Procknow, et al.
Bone Marrow Transplantation|July 19, 2005
Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF aloneS M Devine, R A Brown, V Mathews, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2003
Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantationH Khoury, K Trinkaus, M J Zhang, et al.
Bone Marrow Transplantation|November 18, 2008
Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBIT E Druley, R Hayashi, D B Mansur, et al.
Bone Marrow Transplantation|April 1, 1995
Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 yearsA P Rapoport, J F DiPersio, B A Martin, et al.
Bone Marrow Transplantation|July 29, 2014
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myelomaT-F Wang, M A Fiala, A F Cashen, et al.
Bone Marrow Transplantation|March 14, 2000
Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamideR E Duerst, J T Horan, J L Liesveld, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 19, 2011
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literatureJ S Chawla, A Ghobadi, J Mosley, et al.
Bone Marrow Transplantation|July 5, 2001
Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulinH Khoury, A Kashyap, D R Adkins, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Blood|December 10, 1999
Ex vivo cultured megakaryocytes express functional glycoprotein IIb-IIIa receptors and are capable of adenovirus-mediated transgene expressionN Faraday, J J Rade, D C Johns, et al.
Bone Marrow Transplantation|January 14, 2009
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATGM G Martin, G L Uy, E Procknow, et al.
Bone Marrow Transplantation|July 19, 2005
Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF aloneS M Devine, R A Brown, V Mathews, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2003
Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantationH Khoury, K Trinkaus, M J Zhang, et al.
Bone Marrow Transplantation|November 18, 2008
Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBIT E Druley, R Hayashi, D B Mansur, et al.
Bone Marrow Transplantation|April 1, 1995
Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 yearsA P Rapoport, J F DiPersio, B A Martin, et al.
Bone Marrow Transplantation|July 29, 2014
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myelomaT-F Wang, M A Fiala, A F Cashen, et al.
Bone Marrow Transplantation|March 14, 2000
Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamideR E Duerst, J T Horan, J L Liesveld, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 19, 2011
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literatureJ S Chawla, A Ghobadi, J Mosley, et al.
Bone Marrow Transplantation|July 5, 2001
Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulinH Khoury, A Kashyap, D R Adkins, et al.
Pageof 9